Download a complete bibliography from each of our ongoing investigational programs below.
Tebipenem HBR
Antimicrobial susceptibility patterns of common complicated urinary tract infection pathogens in US Hospitals, 2013-2018
Tebipenem HBR
Resistance to oral antibiotics among urinary tract infection isolates of Escherichia coli from the United States and Europe in 2017
Tebipenem HBR
Epidemiology, empiric treatment, and outcomes among hospitalized patients with complicated urinary tract infections in the US, 2013-2018
SPR206
Akhoundsadegh N, Belanger CR, Hancock REW. Outer Membrane Interaction Kinetics of New Polymyxin B Analogs in Gram-Negative Bacilli. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00935-19.
Tebipenem HBR
Single- and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose
Tebipenem HBR
Eckburg PB, Jain A, Walpole S, et al. Safety, pharmacokinetics, and food effect of tebipenem pivoxil hydrobromide after single and multiple ascending oral doses in healthy adult subjects. Antimicrob Agents Chemother. 2019 Aug 23;63(9):e00618-19.
Tebipenem HBR
McEntee L, Johnson A, Farrington N, et al. Pharmacodynamics of tebipenem: New options for oral treatment of multidrug-resistant gram-negative infections. Antimicrob Agents Chemother. 2019 Jul 25;63(8): e00603-19.
SPR720
In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera
SPR206
A GLP 14-day repeat dose toxicology study of SPR206 in monkeys
SPR720
SPR720: novel oral therapy for non-tuberculous Mycobacterial (NTM) infections
SPR720
A GLP 28-day repeat dose toxicology study of SPR720 in monkeys
SPR206
The impact of varied test conditions on the in vitro activity of SPR206, a next-generation polymyxin B analog, against drug-susceptible and multidrug-resistant gram-negative pathogens
Tebipenem HBR
Single-and multiple-ascending dose (SAD/MAD) study demonstrates the human pharmacokinetics (PK) and tolerability of SPR994 (tebipenem pivoxil hydrobromide), an oral carbapenem (CP), at the predicted therapeutic dose
SPR206
In vivo efficacy of SPR206 in murine lung and thigh infection models caused by multi-drug resistant pathogens Pseudomonas aeruginosa and Acinetobacter baumannii
SPR720
In vitro activity of SPR719 against non-Tuberculosis Mycobacterium strains of Mycobacterium ulcerans, Mycobacterium marinum, and Mycobacterium chimaera - pipeline drugs to treat
SPR206
Mechanism of action of SPR206, a next-generation polymyxin active against gram-negative pathogens
SPR720
Evaluating the sterilizing activity of SPR720 in combination therapy against Mycobacterium tuberculosis infection in mice
Tebipenem HBR
Evaluation of tebipenem activity tested against a collection of isogenic Escherichia coli strains producing various clinically relevant β-lactamases
SPR206
Activity of investigational polymyxin-B-like compound (SPR206) against set of Enterobacteriaceae organisms responsible for human infections
SPR206
In vivo efficacy of next-generation polymyxin SPR206 in an immunocompetent murine ascending UTI infection model caused by Escherichia coli
SPR206
Optimization of next-generation polymyxins leading to SPR206 as a development candidate
Tebipenem HBR
SPR994: oral carbapenem for the treatment of complicated urinary tract infections
SPR206
SPR206: Next generation polymyxin for the treatment of highly resistant gram-negative bacterial infections
SPR206
In vitro bactericidal activity of next-generation polymyxin SPR206 against susceptible and multidrug-resistant (MDR) Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae as compared to levofloxacin and meropenem
Tebipenem HBR
Monitoring the in vitro activity of tebipenem, an orally available carbapenem agent, against a current collection of surveillance Enterobacteriaceae clinical isolates (2018)
Tebipenem HBR
The burden of resistance among urinary tract isolates of Escherichia coli in the United States in 2017
Tebipenem HBR
Arends SJR, Rhomberg PR, Cotroneo N, et al. Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae isolates, including a challenge set of organisms. Antimicrob Agents Chemother. 2019 May 24;63(6):e02618-18.
Tebipenem HBR
Activity of tebipenem, an oral carbapenem, against multidrug-resistant urinary tract infection-causing pathogens with characterized resistance mechanisms collected in Europe and the United States in 2016
Tebipenem HBR
Escherichia coli from urinary tract infections in Europe in 2017 are increasingly multidrug-resistant to oral antibiotics in an era of co-resistance to extended-spectrum beta-lactamases
Tebipenem HBR
Lacasse E, Brouillette E, Larose A, et al. In vitro activity of tebipenem (SPR859) against penicillin-binding proteins of gram-negative and gram-positive bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
Thomas J, Navre M, Rubio A, Coukell A. Shared Platform for Antibiotic Research and Knowledge: A Collaborative Tool to SPARK Antibiotic Discovery. ACS Infect Dis. 2018 Nov 9;4(11):1536-1539.
SPR720
Brown-Elliott BA, Rubio A, Wallace RJ Jr. In Vitro Susceptibility Testing of a Novel Benzimidazole, SPR719, against Nontuberculous Mycobacteria. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e01503-18.
Tebipenem HBR
Rubio A, Pucci MJ, Jain A. Characterization of SPR994, an orally available carbapenem, with activity comparable to intravenously administered carbapenems. ACS Infect Dis. 2018 Oct 12;4(10):1436-1438.
Tebipenem HBR
Patient demographics and comorbidity profiles associated with hospitalized patients admitted with resistant versus susceptible urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
SPR994 (oral carbapenem prodrug): what’s in the pipeline?
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of SPR994 for multidrug resistant Enterobacteriaceae
SPR206
Activity of investigational polymyxin-B-like compound (SPR206) against set of Enterobacteriaceae organisms responsible for human infections
SPR206
In vivo efficacy of SPR206 in murine lung and thigh infection models caused by multi-drug resistant pathogens Pseudomonas aeruginosa and Acinetobacter baumannii
Tebipenem HBR
The impact of antibiotic resistance on hospitalized patients with Enterobacteriaceae (ENT) urinary tract infections (UTI): a multicenter analysis
Tebipenem HBR
Pharmacokinetics and pharmacodynamics of tebipenem (SPR859) for multidrug resistant Enterobacteriaceae in a hollow fibre infection model
SPR206
Understanding the SAR interplay for kidney exposure and cytotoxicity facilitates the design of improved polymyxin derivatives – identification of SPR206 as a development candidate
Tebipenem HBR
Current oral (PO) regimen options are suboptimal for hospitalized patients with urinary tract infections (UTI) due to contemporary resistant Enterobacteriaceae (ENT): a multicenter analysis
SPR206
In vivo efficacy of SPR206 in an immunocompetent murine ascending UTI infection model caused by Escherichia coli
SPR206
In vitro activity evaluation of a next-generation polymyxin, SPR206, against non-fermentative gram-negative bacilli responsible for human infections
Tebipenem HBR
Jain A, Utley L, Parr TR, et al. Tebipenem, the first oral carbapenem antibiotic. Expert Rev Anti Infect Ther. 2018 Jul;16(7):513-522.
SPR720
Potent activity of a novel gyrase inhibitor (SPR719/SPR720) in vitro and in a prolonged acute Mycobacterium abscessus mouse model of infection
Tebipenem HBR
In vivo efficacy of tebipenem-pivoxil (SPR994) in neutropenic murine lung models of gram-negative bacterial infection
SPR720
In vitro characterization of a novel gyrase inhibitor (SPR719) against nontuberculous Mycobacteria
Unable to find what you were looking for?
Download a complete bibliography from each of our ongoing investigational programs below.
